viewFrontier IP Group PLC

Frontier IP investee firm in tie up to find next wave of cancer drugs

Evotec and ex scientia’s will use the Dundee-based firm's algorithmic design platform to identify drug candidates.

There are two new foot soldiers in the battle to beat cancer.

Frontier IP Group Plc (LON:FIPP) investee company ex scientia is teaming up with Germany’s Evotec discover the next wave of immuno-oncology drugs that use the body’s immune system to attack the killer disease.

The two will use Dundee-based ex scientia’s algorithmic design platform to identify candidates.

Researchers are screening for bispecific small molecules, which are capable of binding to two different targets rather than one.

The focus initially will be cancer-related adenosine targets, which are recognised to play important roles in the emerging field of immuno-oncology.

Combining these adenosine-based mechanisms with other targets “holds great promise in boosting efficacy and addressing larger patient populations through a single small molecule drug”, Evotec said in press release.

Andrew Hopkins, chief executive of ex Scientia, hailed the tie-up with the Germans.

"This is an ideal partnership to develop an innovative immuno-oncology portfolio where our focus is on delivering efficacious drug candidates to tackle the inherent challenges of the complex biology,” he said.

“Evotec have an excellent track record in project delivery and their proven track record in regarding efficiency gains in drug discovery chime with our own."

Quick facts: Frontier IP Group PLC

Price: 62.23 GBX

Market: AIM
Market Cap: £34.23 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Frontier IP Group PLC named herein, including the promotion by the Company of Frontier IP Group PLC in any Content on the Site, the Company...


Frontier IP Group PLC chief sees first investee IPO by the end of 2017

Neil Crabb, chief executive of Frontier IP Group PLC (LON:FIPP) says a number of its investee companies “are beginning to see significant commercial traction now.” In terms of an upcoming IPO for any of its investee firms, he says: “There are a number of companies in the portfolio...

on 03/09/2016

2 min read